2022
DOI: 10.1101/2022.06.12.495737
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

In silico, in vitro, and in vivo models reveal EPHA2 as a target for decreasing inflammation and pathological endochondral ossification in osteoarthritis

Abstract: Low-grade inflammation and pathological endochondral ossification are processes that underlie the progression of osteoarthritis. In this study, data mining on publicly available transcriptomic datasets revealed EPHA2 to be associated both with inflammation and endochondral ossification in osteoarthritis. EPHA2 was further investigated using a computational model of cellular signaling networks in chondrocytes. In silico activation of EPHA2 increased inflammatory mediators and triggered the hypertrophic differen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 71 publications
(149 reference statements)
0
1
0
Order By: Relevance
“…Joint defects typically present elevated levels of tumor necrosis factor-α (TNF-α) and interleukins with inflamed synovium that downregulates extracellular matrix (ECM) production and the anabolic activity of the cells [57][58][59]. To reduce inflammation in joints, triamcinolone acetonide (TA) can be administered [60][61][62][63][64]; and site-specific delivery of drugs from biomaterials circumvents systemic pharmacokinetic challenges and off-target effects [65]. Scaffolds loaded with drugs/bioactives provide dual functionality in terms of local delivery of the payload in the extracellular environment, as well as serving as a support for the cells to organize in a 3D fashion [66][67][68].…”
Section: Introductionmentioning
confidence: 99%
“…Joint defects typically present elevated levels of tumor necrosis factor-α (TNF-α) and interleukins with inflamed synovium that downregulates extracellular matrix (ECM) production and the anabolic activity of the cells [57][58][59]. To reduce inflammation in joints, triamcinolone acetonide (TA) can be administered [60][61][62][63][64]; and site-specific delivery of drugs from biomaterials circumvents systemic pharmacokinetic challenges and off-target effects [65]. Scaffolds loaded with drugs/bioactives provide dual functionality in terms of local delivery of the payload in the extracellular environment, as well as serving as a support for the cells to organize in a 3D fashion [66][67][68].…”
Section: Introductionmentioning
confidence: 99%